RDPTF (Radiopharm Theranostics) Debt-to-Asset : 0.00 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Debt-to-Asset?

Radiopharm Theranostics RDPTF Debt-to-Asset is 0.00 as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. Radiopharm Theranostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. Radiopharm Theranostics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2025 was $56.30 Mil. Radiopharm Theranostics's debt to asset for the quarter that ended in Jun. 2025 was 0.00.

Radiopharm Theranostics  (OTCPK:RDPTF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Radiopharm Theranostics Debt-to-Asset Related Terms

Radiopharm Theranostics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Debt-to-Asset Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Debt-to-Asset
0.00 0.00 0.00 0.00

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Debt-to-Asset Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

RDPTF vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Debt-to-Asset falls into.


Radiopharm Theranostics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Radiopharm Theranostics's Debt-to-Asset for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 56.303
=0.00

Radiopharm Theranostics's Debt-to-Asset for the quarter that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 56.303
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Radiopharm Theranostics (RDPTF) has a Debt-to-Asset of 0.00 as of Jun. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Debt-to-Asset too high?
Radiopharm Theranostics' current Debt-to-Asset is 0.00.
How does Radiopharm Theranostics' Debt-to-Asset compare to VRTX and REGN?
Radiopharm Theranostics' Debt-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current Debt-to-Asset is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USARAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.